Inflammatory Bowel Disease
Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.
What if your medical degree could launch more than a clinical career? In this candid and compelling read, Dr Jon Edelson shares his lessons for early-career doctors ready to think beyond the bedside and explore the business of medicine.
In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.
New research has shown that infliximab clearance is increased in patients hospitalized with severe ulcerative colitis, potentially leading to a higher risk of underexposure when standard dosing regimens are used. The study, which analyzed infliximab pharmacokinetics in 154 patients with ulcerative colitis, found that patients who were hospitalized exhibited a 35% increase in infliximab clearance compared to outpatients (0.463 L/day vs. 0.339 L/day, p<0.0001). This resulted in subtherapeutic drug levels in the majority of patients from week 2 onwards, with 74% of hospitalized patients having infliximab concentrations below 20 µg/mL at week 2, 69% below 15 µg/mL at week 6, and 56% below 7 µg/mL at week 14.
Research presented at the ACG 2024 Annual Scientific Meeting found no increased risk of major adverse cardiovascular events (MACE) or venous thromboembolism (VTE) in patients with inflammatory bowel disease (IBD) treated with Janus kinase inhibitors (JAKi) compared to those receiving anti-tumor necrosis factor (anti-TNF) therapy. This retrospective cohort study, led by Dr. Saqr Alsakarneh, analyzed data from 7,480 adult patients, showing comparable MACE and VTE rates across both treatment groups, even in older adults. These findings provide reassurance regarding the cardiovascular safety of JAKi in managing IBD, although further prospective studies are needed to validate long-term outcomes.
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
